June 19, 2026
Biogen to acquire RayThera for up to $1bn
Biogen has entered a definitive agreement to acquire RayThera, a biotechnology company specialising in small-molecule therapies for immunology, for up to $1bn.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







